From the outside, clinical supply chain can look like logistics. You make the material, you ship it, you keep it cold. The complexity is not in the broad strokes. It is in the hundred small decisions underneath them, and that is exactly where experience earns its keep.

You cannot force chemistry that is not there. A team does not have to like each other to work well together. This is about leading the team that works but doesn’t quite mesh, when to leave the friction alone, when to step in, and why kindness matters more than closeness.

When a CMO relationship starts to go badly, two instincts kick in. One is to look for the exit. The other is to build the case that they are the problem. Both feel productive, and both are usually wrong.

For most of my career I have had people reporting to me who knew their area better than I did. That is not something I have tried to avoid. It is what I want. This is about what your job actually becomes when you are not the expert in the room.

A commercial launch gets planned down to the day, sometimes the hour, all sequenced backward from the approval date. The hard part is that you commit real money and real decisions before you have the final answers, and sometimes the approval itself changes one of them.

Most temperature excursions I see in distribution are not excursions at all. They are artifacts of how the shipment was packed out, and everyone downstream pays for them anyway. This is about where those false alarms come from, and how to fix the process instead of hiding the signal.

You will never be your CDMO's most important customer, and pretending otherwise wastes energy. But leverage and priority are not the same thing. This is about how a small program earns a CDMO's genuine partnership, especially when the timeline is short and it matters most.

A lean operation has plenty of flexibility and almost no slack, and confusing the two is one of the quieter ways it gets into trouble. Flexibility lets you move the work around. Slack is what lets you survive the week two things go wrong at once.

COVID proved the regulatory machinery can move faster than we're told it can. Then we mostly threw the results away, reverting the changes that worked and normalizing the ones that carried hidden risk. This is about the experiment we ran and never actually read.

A drug product transfer and a drug substance transfer look like the same exercise on paper. One is largely mechanical. The other is live cells, and live cells do not read your project plan. This is about why the two should not be planned the same way.

There is a particular energy in being a team of one, right up until you hit the limit of what one person can hold. This is about what changed when I stopped being the whole function and started building a team, and why letting go turned out to be the harder skill.

Policy says pull back from China. Industry just committed $43 billion in Chinese biotech partnerships in five months. Supply chain teams are caught in the middle, planning around a landscape where the rules and the market are moving in opposite directions.

The cold chain doesn't usually fail because of a single catastrophic event. It fails at the seams. At the handoff points between partners, in the gaps where accountability is unclear, and in markets where the infrastructure isn't built to support the requirements these products demand.

64% of drug launch delays between 2019 and 2024 were caused by manufacturing issues. Biologics now represent 55% of the clinical pipeline. The industry's pipeline is getting harder to manufacture at the exact moment manufacturing is already the primary reason drugs don't make it to market on time.

Running a clinical trial across multiple countries is a fundamentally different undertaking than a domestic one, and the supply chain complexity that comes with it is one of the most consistently underestimated aspects of global clinical development.

2026 is one of the most active years for biotech M&A in recent memory. The headlines focus on the science. What they almost never talk about is the supply chain, and what happens to it after the deal closes.

The push to bring pharmaceutical manufacturing back to the U.S. is real. But there's a significant gap between the policy conversation and the operational reality.

There's a point in the life of most biotech companies where the supply chain demands start to outpace the team's capacity. Fractional leadership fills that gap, and it's one of the most effective and underutilized models in the industry.

Every biotech that works with a contract manufacturer has a quality agreement on file. But there's a significant difference between one that protects you and one that just checks a box.